Results 191 to 200 of about 4,816,902 (277)

STNGS: a deep scaffold learning-driven generation and screening framework for discovering potential novel psychoactive substances. [PDF]

Brief Bioinform
Liu D, Liu D, Sheng K, Cheng Z, Liu Z, Qiao Y, Cai S, Li Y, Wang J, Chen H, Hu C, Xu P, Di B, Liao J.   +13 more
europepmc   +1 more source

Promoting smoking cessation and preventing relapse to tobacco use following a smokefree mental health in‐patient stay: A multi‐centre randomised controlled feasibility study

Addiction, EarlyView.
Abstract Aims This study assessed the feasibility and acceptability of a new theory‐ and evidence‐based intervention designed to prevent return to pre‐admission smoking behaviours after discharge from a smokefree mental health in‐patient setting in the United Kingdom (UK).
Petal Petersen Williams, Lisa Huddlestone, Emily Shoesmith, Jennifer Sweetman, Heidi Stevens, Alex Mitchell, Fraser Wiggins, Lesley Sinclair, Victoria Exley, Catherine Hewitt, Judith Watson, Qi Wu, Jodi Pervin, Moira Leahy, Claire Paul, Lion Shahab, Michelle Horspool, Tim Coleman, Simon Hough, Elena Ratschen, the SCEPTRE Collaboration team, Lesley Colley, Samantha Brady, John Britton, Simon Gilbody, Steve Parrott, Peter Coventry, Gregor Russell, Paul Galdas   +28 more
wiley   +1 more source

Development and validation of a questionnaire to assess knowledge, attitudes, and practices regarding the addictive and detrimental effects of novel psychoactive substances among university students. [PDF]

BMC Public Health
Lu L, Deng J, Li F, Zhu X.
europepmc   +1 more source

From emergence to replacement: The evolution of 3‐methylmethcathinone (3‐MMC) and its substitutes in the Dutch drug market (2012–2024)

Addiction, EarlyView.
Abstract Background and aims The market for new psychoactive substances (NPS) is highly dynamic, with hundreds of substances emerging on the European drug market in the last decade. 3‐methylmethcathinone (3‐MMC), a synthetic cathinone and isomer of mephedrone (4‐MMC), gained popularity in the Netherlands due to its psychostimulant effects and initial ...
Nadia Robert Petronella Wilhelmina Hutten, Pieter Edmond Oomen, Frederiek Schutten, Margriet Walburga van Laar, Laura Alexandra Smit‐Rigter   +4 more
wiley   +1 more source

The association between job loss and alcohol and tobacco use

Addiction, EarlyView.
Abstract Aims This study used Australian longitudinal data to examine the effect of being fired or made redundant on alcohol and tobacco use. Design and setting Fixed effect panel analyses of 19 waves of the Household Income and Labour Dynamics in Australia (HILDA) survey, a voluntary representative longitudinal survey of over 17 000 Australians ...
Don Weatherburn, Sergey Alexeev
wiley   +1 more source

Unable to Describe My Feelings and Emotions Without an Addiction: The Interdependency Between Alexithymia and Addictions

Frontiers in Psychiatry, 2020
Laura Orsolini, Laura Orsolini
doaj   +1 more source

Psychological change processes in alcohol use disorder: A qualitative study of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) with cognitive behavioural therapy

Addiction, EarlyView.
Abstract Background and aims This study qualitatively explored psychological change processes as described by participants and therapists within a phase 2a clinical trial evaluating the safety, tolerability, and preliminary efficacy of a single dose of intranasal 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT; BPL‐003) administered alongside psychological
Mathieu Seynaeve, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, James J. Rucker, Anthony Cleare, John Marsden   +6 more
wiley   +1 more source

Cannabis use disorder in patients prescribed medical cannabis—Should we consider prescription cannabis use disorder as a new diagnostic condition?

Addiction, EarlyView.
Abstract Background and Aims The introduction of prescribed medical cannabis in many parts of the world raises issues regarding how we conceptualise Cannabis Use Disorders (CUD). The Diagnostic Statistical Manual Version 5 (DSM5) provides a framework for ‘Prescription Cannabis Use Disorder’ (Pr‐CUD) when a person is using medical cannabis only‐as ...
Nicholas Lintzeris, Llewellyn Mills
wiley   +1 more source

Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances. [PDF]

Br J Clin Pharmacol, 2020
Deligianni E, Daniel OJ, Corkery JM, Schifano F, Lione LA.   +4 more
europepmc   +1 more source

Marketing features of derived intoxicating cannabinoid product brands on Instagram: A content analysis

Addiction, EarlyView.
Abstract Background and aims Use of derived intoxicating cannabinoid products (DICPs) has grown in the United States (US), as have associated poisonings, emergency department visits and psychotic episodes. Brand marketing on social media, a largely underregulated marketing channel, may be contributing to this growth.
Kathryn La Capria, Siyan Meng, Alisa A. Padon, Kayla K. Tillett, Scott I. Donaldson, Jon‐Patrick Allem, Matthew E. Rossheim, Cassidy LoParco, Carla J. Berg, Kristina M. Jackson, Julia Chen‐Sankey   +10 more
wiley   +1 more source